SY SYK Stryker Corporation Loading... : Bullish and Bearish Analyst Opinions

The 'extra week' in fiscal Q1 contributed approximately $570 million, or 670 bps, to revenue growth, but even excluding that, underlying growth was the strongest in nearly 8 years, indicating robust organic demand. — This indicates strong broad-based market demand across Medtronic's portfolio, not just one-off tailwinds.

Health care and financials broaden market.

Stryker at 200-week MA discount buy

Wolfe Research, JPMorgan, Citizens, Citi, Jefferies, RBC, Wells Fargo, Cantor Fitzgerald.

US pre-market movers show Apple falling on weak China sales and guidance.

Stryker narrows its full-year adjusted earnings outlook while citing increased production needs.

Jefferies lowers its price target on Stryker to 440 dollars from 455 dollars.

Piper Sandler reduces its price forecast for Stryker.

Stryker reported higher profit and revenue amid its cyberattack recovery.

Management raised the lower end of full-year organic sales guidance to 8.3-9.3%, signaling strong demand and production ramp recovery.

UBS, Leerink Partners, BofA, JPMorgan, Truist, Exane BNP Paribas.

Quality healthcare names attract rotation

Stryker trades cheap at 19x earnings.

JNJ called out a modest cost-of-goods-sold tailwind from tariffs in medtech (offset other headwinds), implying some near-term tariff recoupment that may be incremental for the sector. — JNJ's ability to partially offset tariff costs through price or mix suggests a more resilient margin structure, contrasting with competitors who may not have similar leverage.

SYK has 95% predictability of 11-13% annual returns over 28 years, but ROE declined from 18% to 15% and EPS growth slowing to 10-11%. Valuation at 35x P/E vs historical 45x; analysts call it fairly valued. The cyber hack impact and margin compression create near-term uncertainty, but management is confident in recovery. The stock is cheaper than its own history but not a deep value. SYK is a high-quality business best held for long-term compounding, but near-term headwinds and fairly full valuation suggest waiting for a better entry. Hack-related sales losses to competitors may persist; slowing growth may compress multiple further; ROE trend is downward.

The Kobeissi Letter reports President Trump filed 3,642 stock trades including major tech.

Revvity's AI strategy is based on the belief that AI-generated discoveries will create a 'demand bottleneck' for physical validation, requiring more wet lab tools and reagents, positioning them to benefit from the build-out of AI infrastructure in life sciences. — This thesis implies a secular tailwind for lab tools companies as AI accelerates the number of drug targets, potentially benefiting peers like Danaher (DHR) and Thermo Fisher (TMO).

SYK earnings miss larger than feared; cyberattack as excuse.

Earnings miss noted and attributed to cyberattack, with a claim that if transitory.

Bearish view on medtech stocks/ETF as the speaker expects further multiples compression.

Within Ecolab's life sciences business, bioprocessing sales more than doubled in Q1. — Indicates strong demand for biologic manufacturing capacity, benefiting pure-play single-use tech suppliers as they ramp.

"In the case of Stryker, my understanding is they went and disrupted an internal login page and that the company told employees to immediately stop using and turn off all of their devices." Cyber attacks that force a company to abruptly halt internal operations and take devices offline can lead to short-term productivity losses, remediation costs, and potential delays in manufacturing or sales cycles. However, if the breach is contained to an internal login page without compromising core IP or patient data, the financial impact may be negligible. WATCH. Monitor Stryker's upcoming disclosures regarding the financial and operational impact of the breach. It presents either a short-term short opportunity if the breach spread laterally, or a buy-the-dip opportunity if the market overreacts to a contained IT incident. The market may completely ignore the news if the company quickly restores systems, resulting in no actionable price movement.

The disruption was widespread. We saw employees say that their devices have been wiped clean of data as a result of this attack... and that other abilities to carry out normal work really have been halted altogether. A total halt of normal work and the wiping of corporate data means Stryker cannot process orders, manufacture devices efficiently, or manage logistics. This will lead to immediate revenue deferrals, lost sales, and massive unbudgeted IT remediation costs that will negatively impact their upcoming quarterly earnings. Short Stryker due to the immediate financial and operational fallout from a successful, destructive cyberattack. The company restores backups faster than anticipated, minimizing the financial impact to a single quarter with no long-term customer loss.

"Cyberattack against the company crippled the company's global operations... many striker employees around the world are unable to work and have been sent home." A global network disruption halting operations will directly impact near-term revenue generation and incur significant, unexpected cybersecurity remediation costs. SHORT SYK due to immediate operational paralysis from a severe cyberattack. Quick resolution of the IT issues and comprehensive cyber insurance covering the bulk of the financial damages.

The tweet shares a link regarding a medical device industry development without providing.

Stryker faces potential security risks after a pro-Iran hacking group claimed responsibility.

Stryker is a top holding in Terry Smith's portfolio; no speaker endorsement.

Medtronic's new Stealth Access spinal surgery system is a new platform designed to integrate with the 70% of US spine procedures that are currently navigated, lowering barriers to robotics adoption. — By leveraging its dominant navigation install base (10,000 units), Medtronic could significantly accelerate robotics adoption in spine surgery, challenging competitors like Stryker and Intuitive Surgical.

Zimmer Biomet is executing a multi-year overhaul of its entire US sales channel, moving from a largely non-dedicated (1099) and non-specialized model to a fully dedicated and specialized one. The company states current productivity is roughly half of direct competitors, and that the transition could take through 2027 to complete. — This deliberate sales disruption in the US is a direct driver of the company's lowered 2026 guidance, signaling a potential near-term share shift in the large-joints market as competitors (Stryker, Enovis, Smith+Nephew) may capitalize on the disruption.

Management guided FY2026 to 8-9.5% organic growth and EPS of $14.90-$15.10, citing record Mako installations, an elevated capital order book, and continued margin expansion despite higher tariffs.